Mr. Shotlander has a strong background in industrial economics and has provided antitrust and litigation services to corporate clients for over a decade – a mix of skill and experience that enables him to pointedly and successfully address the questions and problems faced by his clients.
David Shotlander is an antitrust Partner in the Washington, D.C. office of Haug Partners, focusing his practice on antitrust litigation, government investigations and counseling. Mr. Shotlander has a strong background in industrial economics and has provided antirust and litigation services to corporate clients for over a decade – a mix of skill and experience that enables him to pointedly and successfully address the questions and problems faced by his clients. Mr. Shotlander has represented branded and generic pharmaceutical companies on matters involving critical and emerging antitrust issues, including “reverse payment” litigation. He has also represented parties in merger and civil non-merger investigations before the Federal Trade Commission, Department of Justice and state attorney generals, as well as foreign competition authorities.
Mr. Shotlander’s merger experience includes pre-merger and HSR counseling, second requests and general advocacy before the agencies. In private matters, he has participated in the defense of companies in complex class action litigation and internal investigations on issues pertaining to antitrust, fraud and general business torts, and has significant experience with electronic discovery and motion practice. He has also counseled clients with regard to horizontal collaborations, distribution and licensing practices and antitrust compliance generally. Mr. Shotlander is experienced in economic/data analysis and works closely with economists on many complex matters. Mr. Shotlander’s work has covered many industries but his practice has been most concentrated within the pharmaceutical, grocery and energy sectors.
- Shotlander, David, and Tiffany Jang. “A Look Back at Risk Evaluation and Mitigation Strategies at the Food and Drug Administration in 2020: Year in Review.” Food and Drug Law Institute (FDLI), 11 Dec. 2020, www.fdli.org/2020/12/a-look-back-at-risk-evaluation-and-mitigation-strategies-at-the-food-and-drug-administration-in-2020-year-in-review/.
- David Shotlander and Ralph Labaton. “No FRANDS in Antitrust? Qualcomm's Rejection of FRAND Violations as a Predicate to an Antitrust Violation.” Haug Partners, 6 Oct. 2020, www.haugpartners.com/article/no-frands-in-antitrust-qualcomms-rejection-of-frand-violations-as-a-predicate-to-an-antitrust-violation/.
- David Shotlander and Ralph E. Labaton, “FDA And FTC To Scrutinize Biologics Competition” Haug Partners LLP, February 6, 2020, https://haugpartners.com/article/fda-and-ftc-to-scrutinize-biologics-competition/.
- Shotlander, David. “Pharmaceutical Antitrust Update: Courts Address How and When Product Hopping May Violate the Antirust Laws.” Haug Partners LLP, Haug Partners LLP, 29 Mar. 2017, www.haugpartners.com/article/pharmaceutical-antitrust-update-courts-address-how-and-when-product-hopping-may-violate-the-antirust-laws/.
- SuperLawyers® Washington DC Rising Star, 2014
- Dickinson College, (B.A. Economics and Political Science, 2001)
- George Mason University School of Law, (J.D., 2006)
- District of Columbia
- American Bar Association, Antitrust Section